Cargando…

Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury

Mesenchymal stem cells (MSCs) are a potential therapeutic tool for preventing the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). Herein, we investigated the localization and maintenance of engrafted human bone marrow-derived MSCs in rats subjected to a renal ischemia-reper...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yumi, Nakashima, Ayumu, Doi, Shigehiro, Ishiuchi, Naoki, Kanai, Ryo, Miyasako, Kisho, Masaki, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072868/
https://www.ncbi.nlm.nih.gov/pubmed/33920714
http://dx.doi.org/10.3390/ijms22084178
_version_ 1783684004114857984
author Yamada, Yumi
Nakashima, Ayumu
Doi, Shigehiro
Ishiuchi, Naoki
Kanai, Ryo
Miyasako, Kisho
Masaki, Takao
author_facet Yamada, Yumi
Nakashima, Ayumu
Doi, Shigehiro
Ishiuchi, Naoki
Kanai, Ryo
Miyasako, Kisho
Masaki, Takao
author_sort Yamada, Yumi
collection PubMed
description Mesenchymal stem cells (MSCs) are a potential therapeutic tool for preventing the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). Herein, we investigated the localization and maintenance of engrafted human bone marrow-derived MSCs in rats subjected to a renal ischemia-reperfusion injury (IRI) and compared the effectiveness of two intravascular injection routes via the renal artery or inferior vena cava. Renal artery injection of MSCs was more effective than intravenous injection at reducing IRI-induced renal fibrosis. Additionally, MSCs injected through the renal artery persisted in injured kidneys for over 21 days, whereas MSCs injected through the inferior vena cava survived for less than 7 days. This difference may be attributed to the antifibrotic effects of MSCs. Interestingly, MSCs injected through the renal artery were localized primarily in glomeruli until day 3 post-IRI, and they decreased in number thereafter. In contrast, the number of MSCs localized in tubular walls, and the interstitium increased gradually until day 21 post-IRI. This localization change may be related to areas of damage caused by IRI because ischemia-induced AKI leads to tubular cell damage. Taken together, these findings suggest renal artery injection of MSCs may be useful for preventing the progression of AKI to CKD.
format Online
Article
Text
id pubmed-8072868
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80728682021-04-27 Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury Yamada, Yumi Nakashima, Ayumu Doi, Shigehiro Ishiuchi, Naoki Kanai, Ryo Miyasako, Kisho Masaki, Takao Int J Mol Sci Article Mesenchymal stem cells (MSCs) are a potential therapeutic tool for preventing the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). Herein, we investigated the localization and maintenance of engrafted human bone marrow-derived MSCs in rats subjected to a renal ischemia-reperfusion injury (IRI) and compared the effectiveness of two intravascular injection routes via the renal artery or inferior vena cava. Renal artery injection of MSCs was more effective than intravenous injection at reducing IRI-induced renal fibrosis. Additionally, MSCs injected through the renal artery persisted in injured kidneys for over 21 days, whereas MSCs injected through the inferior vena cava survived for less than 7 days. This difference may be attributed to the antifibrotic effects of MSCs. Interestingly, MSCs injected through the renal artery were localized primarily in glomeruli until day 3 post-IRI, and they decreased in number thereafter. In contrast, the number of MSCs localized in tubular walls, and the interstitium increased gradually until day 21 post-IRI. This localization change may be related to areas of damage caused by IRI because ischemia-induced AKI leads to tubular cell damage. Taken together, these findings suggest renal artery injection of MSCs may be useful for preventing the progression of AKI to CKD. MDPI 2021-04-17 /pmc/articles/PMC8072868/ /pubmed/33920714 http://dx.doi.org/10.3390/ijms22084178 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamada, Yumi
Nakashima, Ayumu
Doi, Shigehiro
Ishiuchi, Naoki
Kanai, Ryo
Miyasako, Kisho
Masaki, Takao
Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title_full Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title_fullStr Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title_full_unstemmed Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title_short Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury
title_sort localization and maintenance of engrafted mesenchymal stem cells administered via renal artery in kidneys with ischemia-reperfusion injury
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072868/
https://www.ncbi.nlm.nih.gov/pubmed/33920714
http://dx.doi.org/10.3390/ijms22084178
work_keys_str_mv AT yamadayumi localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT nakashimaayumu localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT doishigehiro localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT ishiuchinaoki localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT kanairyo localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT miyasakokisho localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury
AT masakitakao localizationandmaintenanceofengraftedmesenchymalstemcellsadministeredviarenalarteryinkidneyswithischemiareperfusioninjury